Table 7.
Targeting mRNA-LNPs to different cell types
| LNP composition | Targeting ligand | Conjugation strategy | mRNA | Ref. |
|---|---|---|---|---|
| MC3, DSPC, Cholesterol, DMG-PEG, and DSPE-PEG (50:10.5:38:1.4:0.1 molar ratio) | Anti-Ly6c mAbs | Modular targeting platform named ASSET (Anchored Secondary scFv Enabling Targeting) was used | Interleukin-10 (IL-10) mRNA; treatment of inflammatory bowel disease | [193] |
| MC3, DSPC, Cholesterol, DMG-PEG, and DSPE-PEG Mal (50:10:38:1.5:0.5 molar ratio) | Anti-CD4 antibody | DTT-reduced IgG was post-inserted into maleimide-functionalized LNPs | Cre recombinase-encoding mRNA | [194] |
| Ionizable cationic lipid (proprietary to Acuitas), phosphatidylcholine, cholesterol, PEG-lipid (50:10:38.5:1.5 molar ratio) | Anti-PECAM-1 antibody | Targeting LNP was generated via SATA–maleimide conjugation chemistry | Luciferase mRNA | [195] |
| Ionizable lipid, DSPC, cholesterol, DMG-PEG, and DSPE-PEG (50:10.5:38:1.4:0.1 molar ratio) | EGFR-antibody | ASSET (Anchored Secondary scFv Enabling Targeting) linker system | Cas9 mRNA and sgRNAs; CRISPR-LNPs against PLK1 | [196] |
| MC3, DSPC, DSPE-PEG2k, DSPE-PEG5k-Mal, Cholesterol (50:10:1.5:0.5:38, molar ratio) | Anti-CD3 antibody | TCEP-reduced IgG was post-inserted into maleimide-functionalized LNPs | mCherry mRNA | [197] |
| Ionizable cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid | Anti-CD5 antibody | Targeting LNP was generated via SATA–maleimide conjugation chemistry | mRNA encoding a CAR designed against fibroblast activation protein (FAP) | [198] |